Patent · US Active

Means and methods for treating DLBCL

US9192665B2 · kind B2 · utility

4Cited by

0References

19Claims

0Family size

Assignee

AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

Gerhard Zugmaier · Munich, DE
Dirk Nagorsen · Munich, DE
Juergen Scheele · Munich, DE

Key dates

Filing date	Oct 27, 2011
Grant date	Nov 24, 2015
Priority date	—
Expiry date	Nov 22, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.